CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle

Guntram Schernthaner, Christoph Wanner, Dubravka Jurišić-Eržen, Cristian Guja, Janusz Gumprecht, Iwona R. Jarek-Martynowa, Avraham Karasik, Nebojša Lalić, Boris N. Mankovsky, Martin Prázný, Tsvetalina Tankova, Anat Tsur, Thomas C. Wascher, I. Wittmann

Research output: Contribution to journalComment/debate

Abstract

Dipeptidyl peptidase-4 (DPP-4)inhibitors are a class of glucose-lowering agent for type 2 diabetes (T2D)that are commonly used in clinical practice. With the recent disclosure of data from the CARMELINA cardiovascular outcomes trial (CVOT), which investigated linagliptin, CV and renal outcomes data are now available for four agents in the DPP-4 inhibitor class that are approved in most markets. To consider how the CARMELINA study may be interpreted, and the relevance for our clinical practice, we convened as an expert group of diabetes specialists from the Central and Eastern Europe region to discuss the new disclosures. Our discussions revealed a general confidence in safety across the class that is further supported by CARMELINA. However, we also concluded that there are important differences in the available evidence level between agents in the setting of heart failure and data on renal outcomes. Here, we noted the clinical relevance to our practice of the study population in CARMELINA, which is unique among CVOTs in including a majority of patients with chronic kidney disease (CKD). Given the risk for future development of renal impairment that is associated with T2D even in patients without current overt CKD, we believe that the CARMELINA study provides important new insights that are clinically relevant for a broad range of patients. Finally, we discuss how these insights can be integrated into the approach to the pharmacotherapeutic management of hyperglycaemia that is recommended in newly updated guidelines.

Original languageEnglish
Pages (from-to)30-40
Number of pages11
JournalDiabetes Research and Clinical Practice
Volume153
DOIs
Publication statusPublished - Jul 1 2019

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Disclosure
Chronic Renal Insufficiency
Kidney
Type 2 Diabetes Mellitus
Eastern Europe
Hyperglycemia
Heart Failure
Guidelines
Safety
Glucose
Population

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Schernthaner, G., Wanner, C., Jurišić-Eržen, D., Guja, C., Gumprecht, J., Jarek-Martynowa, I. R., ... Wittmann, I. (2019). CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle. Diabetes Research and Clinical Practice, 153, 30-40. https://doi.org/10.1016/j.diabres.2019.05.013

CARMELINA : An important piece of the DPP-4 inhibitor CVOT puzzle. / Schernthaner, Guntram; Wanner, Christoph; Jurišić-Eržen, Dubravka; Guja, Cristian; Gumprecht, Janusz; Jarek-Martynowa, Iwona R.; Karasik, Avraham; Lalić, Nebojša; Mankovsky, Boris N.; Prázný, Martin; Tankova, Tsvetalina; Tsur, Anat; Wascher, Thomas C.; Wittmann, I.

In: Diabetes Research and Clinical Practice, Vol. 153, 01.07.2019, p. 30-40.

Research output: Contribution to journalComment/debate

Schernthaner, G, Wanner, C, Jurišić-Eržen, D, Guja, C, Gumprecht, J, Jarek-Martynowa, IR, Karasik, A, Lalić, N, Mankovsky, BN, Prázný, M, Tankova, T, Tsur, A, Wascher, TC & Wittmann, I 2019, 'CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle', Diabetes Research and Clinical Practice, vol. 153, pp. 30-40. https://doi.org/10.1016/j.diabres.2019.05.013
Schernthaner G, Wanner C, Jurišić-Eržen D, Guja C, Gumprecht J, Jarek-Martynowa IR et al. CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle. Diabetes Research and Clinical Practice. 2019 Jul 1;153:30-40. https://doi.org/10.1016/j.diabres.2019.05.013
Schernthaner, Guntram ; Wanner, Christoph ; Jurišić-Eržen, Dubravka ; Guja, Cristian ; Gumprecht, Janusz ; Jarek-Martynowa, Iwona R. ; Karasik, Avraham ; Lalić, Nebojša ; Mankovsky, Boris N. ; Prázný, Martin ; Tankova, Tsvetalina ; Tsur, Anat ; Wascher, Thomas C. ; Wittmann, I. / CARMELINA : An important piece of the DPP-4 inhibitor CVOT puzzle. In: Diabetes Research and Clinical Practice. 2019 ; Vol. 153. pp. 30-40.
@article{4caee345c96e4ef0a8c115272eb683ca,
title = "CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle",
abstract = "Dipeptidyl peptidase-4 (DPP-4)inhibitors are a class of glucose-lowering agent for type 2 diabetes (T2D)that are commonly used in clinical practice. With the recent disclosure of data from the CARMELINA cardiovascular outcomes trial (CVOT), which investigated linagliptin, CV and renal outcomes data are now available for four agents in the DPP-4 inhibitor class that are approved in most markets. To consider how the CARMELINA study may be interpreted, and the relevance for our clinical practice, we convened as an expert group of diabetes specialists from the Central and Eastern Europe region to discuss the new disclosures. Our discussions revealed a general confidence in safety across the class that is further supported by CARMELINA. However, we also concluded that there are important differences in the available evidence level between agents in the setting of heart failure and data on renal outcomes. Here, we noted the clinical relevance to our practice of the study population in CARMELINA, which is unique among CVOTs in including a majority of patients with chronic kidney disease (CKD). Given the risk for future development of renal impairment that is associated with T2D even in patients without current overt CKD, we believe that the CARMELINA study provides important new insights that are clinically relevant for a broad range of patients. Finally, we discuss how these insights can be integrated into the approach to the pharmacotherapeutic management of hyperglycaemia that is recommended in newly updated guidelines.",
author = "Guntram Schernthaner and Christoph Wanner and Dubravka Jurišić-Eržen and Cristian Guja and Janusz Gumprecht and Jarek-Martynowa, {Iwona R.} and Avraham Karasik and Nebojša Lalić and Mankovsky, {Boris N.} and Martin Pr{\'a}zn{\'y} and Tsvetalina Tankova and Anat Tsur and Wascher, {Thomas C.} and I. Wittmann",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.diabres.2019.05.013",
language = "English",
volume = "153",
pages = "30--40",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - CARMELINA

T2 - An important piece of the DPP-4 inhibitor CVOT puzzle

AU - Schernthaner, Guntram

AU - Wanner, Christoph

AU - Jurišić-Eržen, Dubravka

AU - Guja, Cristian

AU - Gumprecht, Janusz

AU - Jarek-Martynowa, Iwona R.

AU - Karasik, Avraham

AU - Lalić, Nebojša

AU - Mankovsky, Boris N.

AU - Prázný, Martin

AU - Tankova, Tsvetalina

AU - Tsur, Anat

AU - Wascher, Thomas C.

AU - Wittmann, I.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Dipeptidyl peptidase-4 (DPP-4)inhibitors are a class of glucose-lowering agent for type 2 diabetes (T2D)that are commonly used in clinical practice. With the recent disclosure of data from the CARMELINA cardiovascular outcomes trial (CVOT), which investigated linagliptin, CV and renal outcomes data are now available for four agents in the DPP-4 inhibitor class that are approved in most markets. To consider how the CARMELINA study may be interpreted, and the relevance for our clinical practice, we convened as an expert group of diabetes specialists from the Central and Eastern Europe region to discuss the new disclosures. Our discussions revealed a general confidence in safety across the class that is further supported by CARMELINA. However, we also concluded that there are important differences in the available evidence level between agents in the setting of heart failure and data on renal outcomes. Here, we noted the clinical relevance to our practice of the study population in CARMELINA, which is unique among CVOTs in including a majority of patients with chronic kidney disease (CKD). Given the risk for future development of renal impairment that is associated with T2D even in patients without current overt CKD, we believe that the CARMELINA study provides important new insights that are clinically relevant for a broad range of patients. Finally, we discuss how these insights can be integrated into the approach to the pharmacotherapeutic management of hyperglycaemia that is recommended in newly updated guidelines.

AB - Dipeptidyl peptidase-4 (DPP-4)inhibitors are a class of glucose-lowering agent for type 2 diabetes (T2D)that are commonly used in clinical practice. With the recent disclosure of data from the CARMELINA cardiovascular outcomes trial (CVOT), which investigated linagliptin, CV and renal outcomes data are now available for four agents in the DPP-4 inhibitor class that are approved in most markets. To consider how the CARMELINA study may be interpreted, and the relevance for our clinical practice, we convened as an expert group of diabetes specialists from the Central and Eastern Europe region to discuss the new disclosures. Our discussions revealed a general confidence in safety across the class that is further supported by CARMELINA. However, we also concluded that there are important differences in the available evidence level between agents in the setting of heart failure and data on renal outcomes. Here, we noted the clinical relevance to our practice of the study population in CARMELINA, which is unique among CVOTs in including a majority of patients with chronic kidney disease (CKD). Given the risk for future development of renal impairment that is associated with T2D even in patients without current overt CKD, we believe that the CARMELINA study provides important new insights that are clinically relevant for a broad range of patients. Finally, we discuss how these insights can be integrated into the approach to the pharmacotherapeutic management of hyperglycaemia that is recommended in newly updated guidelines.

UR - http://www.scopus.com/inward/record.url?scp=85066333425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066333425&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2019.05.013

DO - 10.1016/j.diabres.2019.05.013

M3 - Comment/debate

AN - SCOPUS:85066333425

VL - 153

SP - 30

EP - 40

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

ER -